Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Assoc. Prof. Joerg Herrmann
Dr. Cardinale provided an overview of the various aspects of radiation-induced heart disease, including coronary, valvular, and pericardial heart disease. These are mainly chronic disease processes, encountered as complications of therapies decades ago. The impact of new chest radiation techniques remains to be seen, and will provide further answers on whether the dose-effect relationship is linear or exponential, i.e. with or without a threshold dose.
An important patient subset in need of management refinement includes patients across the spectrum of coronary artery disease. Dr. Force reviewed new discoveries on the role of topoisomerase II-beta on anthracycline-induced cardiotoxicity, and as it is inhibited by dexrazoxane, the related renewed interest in this drug as a preventive agent.
However, as Dr. Eschenhagen pointed out, the European Medicines Agency (in keeping with U.S. recommendations) restricted the use of dexrazoxane to patients with advanced or metastatic breast cancer who have already received 300 mg/m2 doxorubicin or 540 mg/m2 epirubicin. The spectrum of cardiovascular side effects with tyrosine kinase inhibitors will continue to evolve as kinases are an integral component of the cardiomyocyte enzymatic machinery, leading to unavoidable “off-target” effects. For this reason, the call for better preclinical and clinical screening modalities is very eminent.
Finally, Dr. von Haehling presented intriguing experimental data on how cancer (tissue) itself (i.e. without any of the above cancer treatment modalities) can lead to cardiomyopathy over time. Clearly, this will need to be assessed further in the clinical arena. In summary, then, there is a need to treat cancer with the least amount of “collateral cardiovascular damage”.
Session Title: Cardiology meets oncology
© 2016 European Society of Cardiology. All rights reserved